A股、港股医药股反弹，药明康德盘中大涨超9%

Core Viewpoint - The article highlights a rebound in the pharmaceutical sector of A-shares and Hong Kong stocks following a significant drop, driven by strong earnings reports from key companies like WuXi AppTec and Yaoshibang, as well as positive developments in innovative drug companies [3][4][6]. Group 1: Company Performance - WuXi AppTec reported a revenue of 45.456 billion yuan for 2025, a year-on-year increase of 15.84%, with a net profit of 19.151 billion yuan, up 102.65% [4]. - The company expects its overall revenue for 2026 to reach between 51.3 billion and 53 billion yuan, representing a growth of 12.86% to 16.6% [5]. - Yaoshibang achieved a revenue of 20.9 billion yuan for 2025, a 17.1% increase, with a net profit of 150 million yuan, up 409% [6]. Group 2: Market Reaction - Following the earnings reports, WuXi AppTec's stock price surged by 6% in A-shares and over 9% in Hong Kong [6]. - Other pharmaceutical stocks in both markets also experienced significant gains, with several stocks rising over 4% [6]. Group 3: Innovative Drug Developments - Innovative drug company Kangnuo announced a collaboration with OuroMedicines, which is set to be acquired by Gilead Sciences for a total of up to 2.175 billion USD [8]. - Kangnuo stands to gain approximately 320 million USD from this acquisition, enhancing its financial position [9].